1. Panaxadiol as a major metabolite of AD-1 can significantly inhibit the proliferation and migration of breast cancer cells: In vitro and in vivo study.
- Author
-
Xu, Lei, Zhang, Xiaoshu, Xiao, Shengnan, Li, Xiaofei, Jiang, Hua, Wang, Ziyi, Sun, Baoshan, and Zhao, Yuqing
- Subjects
- *
CANCER cell migration , *CANCER cells , *BREAST cancer , *METASTATIC breast cancer , *IN vivo studies , *CELL migration - Abstract
[Display omitted] • M2 (PD) is the main metabolite of dammarane ginsenoside AD-1 in vivo. • Compound M3 was isolated from metabolites in vivo for the first time. • PD could significantly inhibit the proliferation and migration of MDA-MB-231 cells and induce G1-phase arrest. • PD could significantly inhibit the proliferation and migration of breast cancer in nude mice. • PD inhibited proliferation and metastasis of breast cancer cells by inducing the p38 MAPK/MMP9 pathway. Previous studies have shown that 20 (R)-25-methoxyl-dammarane-3 β , 12 β , 20 triol (AD-1) can inhibit various cancer cell lines. This study aimed to explore the effect and mechanism of AD-1 metabolite M2 (Panaxadiol; PD) on breast cancer cells of nude mice. Five AD-1 metabolites were isolated and identified using various chromatographic techniques. PD was the main component. In vitro results showed that PD could inhibit the proliferation and migration of MDA-MB-231 cells by inducing G1-phase arrest. In addition, PD down-regulated the expression of Cyclin D1, cdk2, cdk4, cdk6, P-p38, and MMP9, and up-regulated p21 and p27. In vivo results showed that PD could effectively reduce the volume, weight, and migration of breast cancer Transcriptomics analyzed 491 differentially expressed genes by GO and KEGG enrichment. RT-PCR verification confirmed that the significant down-regulation of MMP9 was consistent with transcriptomics results. In further research showed that PD regulated the protein expression of P-p38 and MMP9 in MAPK pathway. In summary, in vivo and in vitro studies showed that PD significantly inhibit the occurrence and development of breast cancer, possibly through the MAPK pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF